Stonegate Capital Partners has initiated coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage life sciences company focused on developing central nervous system (CNS) therapeutics designed to overcome the blood–brain barrier. The announcement, made on January 9th, 2026, underscores the potential of NeOnc's pipeline, particularly its lead asset NEO100.
NEO100 is a patented, pure pharmaceutical compound produced via proprietary synthesis for pharmaceutical-grade purity and reproducibility. The company's intranasal administration strategy aims to access the brain via olfactory and trigeminal pathways, offering a non-invasive route intended to improve adherence and enable more direct delivery. Stonegate views NTHI as a differentiated platform, supported by favorable tolerability with prolonged dosing and multiple near-term catalysts as the program advances toward a 2026 readout.
Key takeaways from the initiation include positive Phase 1/2a results for NEO100 announced in December, a top-line Phase 2a readout expected in mid-2026, and the expected near-term closing and funding of the Quazar investment. These milestones are crucial for the company's progress in developing treatments for CNS disorders, a therapeutic area with significant unmet medical need.
For more details, the full announcement can be accessed here. The coverage initiation by Stonegate Capital Partners, a leading capital markets advisory firm, provides increased visibility for NeOnc as it advances its clinical programs. The company's innovative approach to drug delivery across the blood-brain barrier could address challenges in treating brain tumors and other neurological conditions.
The upcoming Phase 2a readout in mid-2026 will be a critical event for NeOnc, potentially validating the efficacy of NEO100 and setting the stage for further development. Additionally, the Quazar investment is expected to provide financial support for ongoing operations and pipeline advancement.
Stonegate Capital Partners, through its affiliate Stonegate Capital Markets (member FINRA), offers a full spectrum of investment banking services for public and private companies. This coverage initiation may attract investor attention to NeOnc's promising therapeutic approach and its potential to address significant CNS treatment gaps.
